Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 3/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.43 |
| ▸ | PIK3C2B | O00750 | 3/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 6/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | CTRC | Q99895 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.39 |
| ▸ | CCR2 | P41597 | 2/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496733 | 0.90 | ALOX5AP (0.47) | DCTPP1ALOX5APPTGESALOX5LTC4S | |
| SCHEMBL6503273 | 0.89 | CYP1A2 (0.42) | AGTR1PPARG | |
| SCHEMBL6172911 | 0.87 | PPARG (0.48) | DCTPP1PIK3C2BPPARGCCR2 | |
| SCHEMBL7130975 | 0.87 | DCTPP1 (0.51) | DCTPP1AGTR1PPARGAGTR2 | |
| SCHEMBL6498493 | 0.86 | DCTPP1 (0.40) | DCTPP1ALOX5APPTGESALOX5LTC4S | |
| SCHEMBL6491148 | 0.85 | DCTPP1 (0.45) | DCTPP1ALOX5APPTGESALOX5LTC4S | |
| SCHEMBL6492577 | 0.84 | DCTPP1 (0.41) | DCTPP1ALOX5APPTGESALOX5LTC4S | |
| SCHEMBL6307363 | 0.84 | PPARG (0.51) | ALOX5APPTGESALOX5LTC4SAGTR1 | |
| SCHEMBL6501198 | 0.83 | NR4A2 (0.48) | ALOX5APPPARGDHODH | |
| SCHEMBL6498830 | 0.83 | PIK3C2B (0.41) | DCTPP1ALOX5APPTGESALOX5LTC4S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | DCTPP1 1534/4885ALOX5AP 4663/4885PTGES 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.